{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:02:56Z","timestamp":1774684976696,"version":"3.50.1"},"reference-count":54,"publisher":"Pharmaceutical Society of Japan","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,11,1]]},"DOI":"10.1248\/bpb.b21-00382","type":"journal-article","created":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T22:09:12Z","timestamp":1635718152000},"page":"1697-1706","source":"Crossref","is-referenced-by-count":16,"title":["Methylglyoxal-Derived Advanced Glycation End Products (AGE4) Promote Cell Proliferation and Survival in Renal Cell Carcinoma Cells through the RAGE\/Akt\/ERK Signaling Pathways"],"prefix":"10.1248","volume":"44","author":[{"given":"Han-Kyul","family":"Nam","sequence":"first","affiliation":[{"name":"Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So-Ra","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Cheol","family":"Pyo","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Keun","family":"Ha","sequence":"additional","affiliation":[{"name":"Division of Functional Food Research, Korea Food Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi-Hyun","family":"Nam","sequence":"additional","affiliation":[{"name":"Sue Anschutz-Rodgers Eye Center and Department of Ophthalmology, University of Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang-Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Nam M-H, Lee H-S, Seomun Y, Lee Y, Lee K-W. Monocyte-endothelium-smooth muscle cell interaction in co-culture: proliferation and cytokine productions in response to advanced glycation end products. Biochim. Biophys. Acta<\/i>, 1810<\/b>, 907\u2013912 (2011).","DOI":"10.1016\/j.bbagen.2011.06.005"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Moldogazieva NT, Mokhosoev IM, Mel\u2019nikova TI, Porozov YB, Terentiev AA. Oxidative stress and advanced lipoxidation and glycation end products (ALEs and AGEs) in aging and age-related diseases. Oxid. Med. Cell. Longev.<\/i>, 2019<\/b>, 3085756 (2019).","DOI":"10.1155\/2019\/3085756"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Byun K, Yoo Y, Son M, Lee J, Jeong G-B, Park YM, Salekdeh GH, Lee B. Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases. Pharmacol. Ther.<\/i>, 177<\/b>, 44\u201355 (2017).","DOI":"10.1016\/j.pharmthera.2017.02.030"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ahmed N. Advanced glycation endproducts\u2013role in pathology of diabetic complications. Diabetes Res. Clin. Pract.<\/i>, 67<\/b>, 3\u201321 (2005).","DOI":"10.1016\/j.diabres.2004.09.004"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, Cooper ME. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via<\/i> the receptor for advanced glycation end products (RAGE). J. Clin. Invest.<\/i>, 108<\/b>, 1853\u20131863 (2001).","DOI":"10.1172\/JCI11951"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Jan R, Chaudhry GE. Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv. Pharm. Bull.<\/i>, 9<\/b>, 205\u2013218 (2019).","DOI":"10.15171\/apb.2019.024"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Ahmad S, Moinuddin, Dixit K, Shahab U, Alam K, Ali A. Genotoxicity and immunogenicity of DNA-advanced glycation end products formed by methylglyoxal and lysine in presence of Cu2+. Biochem. Biophys. Res. Commun.<\/i>, 407<\/b>, 568\u2013574 (2011).","DOI":"10.1016\/j.bbrc.2011.03.064"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Rhee SY, Kim YS. The role of advanced glycation end products in diabetic vascular complications. Diabetes Metab. J.<\/i>, 42<\/b>, 188\u2013195 (2018).","DOI":"10.4093\/dmj.2017.0105"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ahmad S, Khan H, Siddiqui Z, Khan MY, Rehman S, Shahab U, Godovikova T, Silnikov V, Moinuddin. AGEs, RAGEs and s-RAGE; friend or foe for cancer. Semin. Cancer Biol.<\/i>, 49<\/b>, 44\u201355 (2018).","DOI":"10.1016\/j.semcancer.2017.07.001"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ, Lotze MT. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J. Transl. Med.<\/i>, 7<\/b>, 17 (2009).","DOI":"10.1186\/1479-5876-7-17"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kim J, Park J-C, Lee MH, Yang CE, Lee JH, Lee WJ. High-mobility group box 1 mediates fibroblast activity via<\/i> RAGE-MAPK and NF-\u03baB signaling in keloid scar formation. Int. J. Mol. Sci.<\/i>, 19<\/b>, 76 (2018).","DOI":"10.3390\/ijms19010076"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Zhang Y, You B, Liu X, Chen J, Peng Y, Yuan Z. High-mobility group box 1 (HMGB1) induces migration of endothelial progenitor cell via<\/i> receptor for advanced glycation end-products (RAGE)-dependent PI3K\/Akt\/eNOS signaling pathway. Med. Sci. Monit.<\/i>, 25<\/b>, 6462\u20136473 (2019).","DOI":"10.12659\/MSM.915829"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Zuccolo E, Di Buduo C, Lodola F, Orecchioni S, Scarpellino G, Kheder DA, Poletto V, Guerra G, Bertolini F, Balduini A, Rosti V, Moccia F. Stromal cell-derived factor-1\u03b1 promotes endothelial colony-forming cell migration through the Ca2+<\/sup>-dependent activation of the extracellular signal-regulated kinase 1\/2 and phosphoinositide 3-kinase\/AKT pathways. Stem Cells Dev.<\/i>, 27<\/b>, 23\u201334 (2018).","DOI":"10.1089\/scd.2017.0114"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Cheng P, Dai W, Wang F, Lu J, Shen M, Chen K, Li J, Zhang Y, Wang C, Yang J, Zhu R, Zhang H, Zheng Y, Guo CY, Xu L. Ethyl pyruvate inhibits proliferation and induces apoptosis of hepatocellular carcinoma via<\/i> regulation of the HMGB1\u2013RAGE and AKT pathways. Biochem. Biophys. Res. Commun.<\/i>, 443<\/b>, 1162\u20131168 (2014).","DOI":"10.1016\/j.bbrc.2013.12.064"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene<\/i>, 26<\/b>, 3291\u20133310 (2007).","DOI":"10.1038\/sj.onc.1210422"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Zlobin A, Bloodworth JC, Osipo C. Mitogen-activated protein kinase (MAPK) signaling. Predictive Biomarkers in Oncology.<\/i> Springer, Cham, pp. 213\u2013221 (2019).","DOI":"10.1007\/978-3-319-95228-4_16"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Wu Y-J, Lin S-H, Din Z-H, Su J-H, Liu C-I. Sinulariolide inhibits gastric cancer cell migration and invasion through downregulation of the EMT process and suppression of FAK\/PI3K\/AKT\/mTOR and MAPKs signaling pathways. Mar. Drugs<\/i>, 17<\/b>, 668 (2019).","DOI":"10.3390\/md17120668"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Wang X, Liu J, Xie Z, Rao J, Xu G, Huang K, Li W, Yin Z. Chlorogenic acid inhibits proliferation and induces apoptosis in A498 human kidney cancer cells via<\/i> inactivating PI 3K\/Akt\/mTOR signalling pathway. J. Pharm. Pharmacol.<\/i>, 71<\/b>, 1100\u20131109 (2019).","DOI":"10.1111\/jphp.13095"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Rabbani N, Thornalley PJ. The critical role of methylglyoxal and glyoxalase 1 in diabetic nephropathy. Diabetes<\/i>, 63<\/b>, 50\u201352 (2014).","DOI":"10.2337\/db13-1606"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Rabbani N, Xue M, Thornalley PJ. Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics. Glycoconj. J.<\/i>, 33<\/b>, 513\u2013525 (2016).","DOI":"10.1007\/s10719-016-9705-z"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Sharaf H, Matou-Nasri S, Wang Q, Rabhan Z, Al-Eidi H, Al Abdulrahman A, Ahmed N. Advanced glycation endproducts increase proliferation, migration and invasion of the breast cancer cell line MDA-MB-231. Biochim. Biophys. Acta<\/i>, 1852<\/b>, 429\u2013441 (2015).","DOI":"10.1016\/j.bbadis.2014.12.009"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Bellier J, Nokin M-J, Lard\u00e9 E, Karoyan P, Peulen O, Castronovo V, Bellahc\u00e8ne A. Methylglyoxal, a potent inducer of AGEs, connects between diabetes and cancer. Diabetes Res. Clin. Pract.<\/i>, 148<\/b>, 200\u2013211 (2019).","DOI":"10.1016\/j.diabres.2019.01.002"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Thilavech T, Abeywardena MY, Dallimore J, Adams M, Adisakwattana S. Cyanidin-3-rutinoside alleviates methylglyoxal-induced cardiovascular abnormalities in the rats. J. Funct. Foods<\/i>, 49<\/b>, 258\u2013266 (2018).","DOI":"10.1016\/j.jff.2018.08.034"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Bold RJ, Termuhlen PM, McConkey DJ. Apoptosis, cancer and cancer therapy. Surg. Oncol.<\/i>, 6<\/b>, 133\u2013142 (1997).","DOI":"10.1016\/S0960-7404(97)00015-7"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Yu Q. Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy. Drug Resist. Updat.<\/i>, 9<\/b>, 19\u201325 (2006).","DOI":"10.1016\/j.drup.2006.03.001"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Fang Z, Tang Y, Jiao W, Xing Z, Guo Z, Wang W, Xu Z, Liu Z. Nitidine chloride induces apoptosis and inhibits tumor cell proliferation via<\/i> suppressing ERK signaling pathway in renal cancer. Food Chem. Toxicol.<\/i>, 66<\/b>, 210\u2013216 (2014).","DOI":"10.1016\/j.fct.2014.01.049"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Gob\u00e9 G, Rubin M, Williams G, Sawczuk I, Buttyan R. Apoptosis and expression of Bcl-2, Bcl-XL, and Bax in renal cell carcinomas. Cancer Invest.<\/i>, 20<\/b>, 324\u2013332 (2002).","DOI":"10.1081\/CNV-120001177"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis<\/i>, 21<\/b>, 485\u2013495 (2000).","DOI":"10.1093\/carcin\/21.3.485"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Dabestani S, Thorstenson A, Lindblad P, Harmenberg U, Ljungberg B, Lundstam S. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J. Urol.<\/i>, 34<\/b>, 1081\u20131086 (2016).","DOI":"10.1007\/s00345-016-1773-y"},{"key":"30","unstructured":"30) \u201cSEER Preliminary Cancer Incidence Rate Estimates for 2017, and diagnosis years 2000 to 2017, SEER 18,\u201d National Cancer Institute. Bethesda, MD.: \u2039https:\/\/seer.cancer.gov\/statistics\/preliminary-estimates\/\u203a, based on the February 2019 SEER data submission."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Graff RE, Sanchez A, Tobias DK, Rodr\u00edguez D, Barrisford GW, Blute ML, Li Y, Sun Q, Preston MA, Wilson KM, Cho E. Type 2 diabetes in relation to the risk of renal cell carcinoma among men and women in two large prospective cohort studies. Diabetes Care<\/i>, 41<\/b>, 1432\u20131437 (2018).","DOI":"10.2337\/dc17-2518"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Graham J, Wells JC, Donskov F, Lee JL, Fraccon A, Pasini F, Porta C, Bowman IA, Bjarnason GA, Ernst DS, Rha SY, Beuselinck B, Hansen A, North SA, Kollmannsberger CK, Wood LA, Vaishampayan UN, Pal SK, Choueiri TK, Heng DYC. Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Eur. Urol. Oncol.<\/i>, 2<\/b>, 643\u2013648 (2019).","DOI":"10.1016\/j.euo.2019.03.007"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J. Urol.<\/i>, 166<\/b>, 1611\u20131623 (2001).","DOI":"10.1016\/S0022-5347(05)65640-6"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer<\/i>, 113<\/b>, 293\u2013301 (2008).","DOI":"10.1002\/cncr.23552"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Abe R, Yamagishi S-i. AGE-RAGE system and carcinogenesis. Curr. Pharm. Des.<\/i>, 14<\/b>, 940\u2013945 (2008).","DOI":"10.2174\/138161208784139765"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z, Falanga V. Research techniques made simple: analysis of collective cell migration using the wound healing assay. J. Invest. Dermatol.<\/i>, 137<\/b>, e11\u2013e16 (2017).","DOI":"10.1016\/j.jid.2016.11.020"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun H, Ringert R. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J. Urol.<\/i>, 160<\/b>, 1914\u20131918 (1998).","DOI":"10.1016\/S0022-5347(01)62443-1"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Millimouno FM, Dong J, Yang L, Li J, Li X. Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. Cancer Prev. Res. (Phila)<\/i>, 7<\/b>, 1081\u20131107 (2014).","DOI":"10.1158\/1940-6207.CAPR-14-0136"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Wu HJ, Che XR, Zheng QL, Wu A, Pan K, Shao AW, Wu Q, Zhang JM, Hong Y. Caspases: a molecular switch node in the crosstalk between autophagy and apoptosis. Int. J. Biol. Sci.<\/i>, 10<\/b>, 1072\u20131083 (2014).","DOI":"10.7150\/ijbs.9719"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Li R, Song Y, Zhou L, Li W, Zhu X. Downregulation of RAGE inhibits cell proliferation and induces apoptosis via<\/i> regulation of PI3K\/AKT pathway in cervical squamous cell carcinoma. Onco. Targets Ther.<\/i>, 13<\/b>, 2385\u20132397 (2020).","DOI":"10.2147\/OTT.S240378"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Chang T, Wang R, Olson DJ, Mousseau DD, Ross AR, Wu L. Modification of Akt1 by methylglyoxal promotes the proliferation of vascular smooth muscle cells. FASEB J.<\/i>, 25<\/b>, 1746\u20131757 (2011).","DOI":"10.1096\/fj.10-178053"},{"key":"42","unstructured":"42) Qie GQ, Wang CT, Chu YF, Wang R. Expression of HMGB1\/RAGE protein in renal carcinoma and its clinical significance. Int. J. Clin. Exp. Pathol.<\/i>, 8<\/b>, 6262\u20136268 (2015)."},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Larsen M, Artym VV, Green JA, Yamada KM. The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr. Opin. Cell Biol.<\/i>, 18<\/b>, 463\u2013471 (2006).","DOI":"10.1016\/j.ceb.2006.08.009"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Senavirathna L, Ma C, Chen R, Pan S. Proteomic investigation of glyceraldehyde-derived intracellular AGEs and their potential influence on pancreatic ductal cells. Cells<\/i>, 10<\/b>, 1005 (2021).","DOI":"10.3390\/cells10051005"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Weigel MT, Kr\u00e4mer J, Schem C, Wenners A, Alkatout I, Jonat W, Maass N, Mundhenke C. Differential expression of MMP-2, MMP-9 and PCNA in endometriosis and endometrial carcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol.<\/i>, 160<\/b>, 74\u201378 (2012).","DOI":"10.1016\/j.ejogrb.2011.09.040"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature<\/i>, 411<\/b>, 342\u2013348 (2001).","DOI":"10.1038\/35077213"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K\/Akt and apoptosis: size matters. Oncogene<\/i>, 22<\/b>, 8983\u20138998 (2003).","DOI":"10.1038\/sj.onc.1207115"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death\u2013apoptosis, autophagy and senescence. FEBS J.<\/i>, 277<\/b>, 2\u201321 (2010).","DOI":"10.1111\/j.1742-4658.2009.07366.x"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Miricescu D, Balan DG, Tulin A, Stiru O, Vacaroiu IA, Mihai DA, Popa CC, Papacocea RI, Enyedi M, Sorin NA, Vatachki G, Georgescu DE, Nica AE, Stefani C. PI3K\/AKT\/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis. Exp. Ther. Med.<\/i>, 21<\/b>, 540 (2021).","DOI":"10.3892\/etm.2021.9972"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Yuen JS, Sim MY, Sim HG, Chong TW, Lau WK, Cheng CW, Ong RW, Huynh H. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma. Int. J. Oncol.<\/i>, 41<\/b>, 712\u2013720 (2012).","DOI":"10.3892\/ijo.2012.1494"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Wu CZ, Zheng JJ, Bai YH, Xia P, Zhang HC, Guo Y. HMGB1\/RAGE axis mediates the apoptosis, invasion, autophagy, and angiogenesis of the renal cell carcinoma. Onco Targets Ther.<\/i>, 11<\/b>, 4501\u20134510 (2018).","DOI":"10.2147\/OTT.S167197"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Tesarova P, Kalousova M, Zima T, Tesar V. HMGB1, S100 proteins and other RAGE ligands in cancer-markers, mediators and putative therapeutic targets. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub.<\/i>, 160<\/b>, 1\u201310 (2016).","DOI":"10.5507\/bp.2016.003"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Prasad K. AGE\u2013RAGE stress: A changing landscape in pathology and treatment of Alzheimer\u2019s disease. Mol. Cell. Biochem.<\/i>, 459<\/b>, 95\u2013112 (2019).","DOI":"10.1007\/s11010-019-03553-4"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Yu W, Hu X, Wang M. Pterostilbene inhibited advanced glycation end products (AGEs)-induced oxidative stress and inflammation by regulation of RAGE\/MAPK\/NF-\u03baB in RAW264. 7 cells. J. Funct. Foods<\/i>, 40<\/b>, 272\u2013279 (2018).","DOI":"10.1016\/j.jff.2017.11.003"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/11\/44_b21-00382\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T03:51:28Z","timestamp":1636170688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/11\/44_b21-00382\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b21-00382","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"article-number":"b21-00382"}}